Sleep-related hypoxia associated with worse outcomes in patients with COVID-19: Study

Cleveland, Ohio: A case-control study by Dr. Cinthya Pena Orbea, MD, and the team revealed that sleep-disordered breathing (SDB) and sleep-related hypoxia is not related to an increased likelihood of contracting SARS-CoV-2 but sleep-related hypoxia is an associated risk factor for harmful COVID-19 outcomes. The findings of the study are published in JAMA Network Open.

Effects of SARS- CoV-2 on sleep-disordered breathing is a common disorder with a range of harmful sequelae. The influence of SDB and sleep-related hypoxemia in SARS-CoV-2 viral infection and COVID-19 outcomes remains unknown. Given the concern for aerosolization with limited data to inform professional society recommendations, whether to continue treatment for SDB with positive airway pressure remains controversial. 

The objective of the study was therefore to investigate the association of SDB and sleep-related hypoxia with SARS-CoV-2 positivity and World Health Organization (WHO)-designated COVID-19 clinical outcomes while accounting for confounding including obesity, underlying cardiopulmonary disease, cancer, and smoking history.

The case-control study was conducted within the Cleveland Clinic Health System (Ohio and Florida) and included all patients who were tested for COVID-19 between March 8 and November 30, 2020 and an available sleep study record. Sleep study identified SDB using the Apnea-Hypopnea Index [AHI] and sleep-related hypoxemia. Outcomes were SARS-CoV-2 infection and WHO-designated COVID-19 clinical outcomes.